|
Market Cap (1-Jul) $2,324,063,488 (333rd) |
Close (30-Jun) $1.14 |
Volume (30-Jun) 2,606,681 |
Shortsold (19-Jun) 79,324,475 (6.21%) (26th) |
|
52w High $3.37 |
52w Low $0.88 |
P/E 454.55 |
EPS -0.13 |
MSB released this announcement to the ASX on 28 February 2023, 8:01. The announcement is marked as price sensitive, and is 110 page(s) in length and 1.67MB in size.
You can view all announcements from MSB and see how they appear on a price chart on the announcements page.
At the date of this announcement, MSB was 4.736% short sold according to ASIC data. It was ranked the 38th most shorted stock on the ASX. It is now ranked as the 26th most shorted stock on the ASX with 6.208% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from MSB | |
|---|---|
| Change of Director's Interest Notice | 13 June 2023, 8:56 |
| Mesoblast Director Appointed to Strategic Advisory Role | 5 June 2023, 9:41 |
| MSB Reports Q3 Financial Results and Operational Highlights | 26 May 2023, 8:32 |
| Half Yearly Report and Accounts | 28 February 2023, 8:01 |
| Mesoblast Second Quarter Financial Results Webcast | 27 February 2023, 11:23 |
| Remestemcel Clinical and Potency Studies Presented at Tandem | 17 February 2023, 9:54 |
| FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP | 9 February 2023, 9:39 |
You must be logged in to post a reply.
Mesoblast 